I 'attended' the virtual AGM. Basically they have set it up at the net and are waiting for Acadia to spike it home. Jon seemed very confident in Acadias ability and, not that he would indicate otherwise, sounded confident the trial will be successful.
Their main focus is now is on developing NNZ-2591 which the cap raise enables them to push ahead with. He was excited by the mouse study results.
They appear to be hoping they are in a position late next year with positive P2 results in NNZ-2591 and P3 results in Trof. If that is the case then who knows what the SP will be. Without doubt the next 18-24 months are make or break.
Ann: AGM Chairman's Address and CEO Presentation, page-12
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3816 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.78 | 2834 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |